Compare Bill.com Holdings Inc (BILL) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bill.com Holdings Inc vs Twist Bioscience Corp — how do they compare? Bill.com Holdings Inc trades at $49.45 (market cap $4.91B), while Twist Bioscience Corp trades at $123.13 (market cap $7.82B). The key difference: Twist Bioscience Corp is the larger of the two by market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Bill.com Holdings Inc nearer its low. Which is the better fit depends on your goals.
| BILL | TWST | |
|---|---|---|
Market Cap | $4.91B | $7.82B |
Sector | Technology | Health |
52-Week High | $56.32 | $124.88 |
52-Week Low | $31.96 | $24.16 |
Enterprise Value | $4.62B | $7.75B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BILL Holdings trades at $47.99, up 2.11% today, with a bullish technical signal from moving averages and strong institutional interest. The company reported revenue growth to $1.46B in 2025 and achieved profitability with net income of $23.80M, marking a significant turnaround from prior losses. Recent news highlights operational efficiency gains from a 30% workforce reduction and strategic focus on AI-driven financial automation for SMBs.
The outlook is positive with consistent earnings beats and analyst consensus favoring a buy rating, though high P/E of 213.91 indicates premium valuation. Key risks include intense fintech competition and reliance on SMB market stability. Upside to the $50.00 high price target depends on sustained margin expansion and successful AI integration.
Twist Bioscience (TWST) trades at $115.67, up 6.04% in the last session, with bullish technical signals from moving averages and a recent analyst upgrade. Revenue growth is strong, with fiscal 2026 Q3 revenue up 23% year-over-year to $118.4 million, though the company remains unprofitable with negative net income margins. A recent $300 million public offering at $96 per share indicates capital raising for expansion.
The outlook is mixed: robust revenue growth and high analyst buy ratings (78.57%) support upside potential, but persistent losses, cash burn, and high valuation ratios pose significant risks. Investors should weigh growth prospects against financial sustainability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bill.com Holdings Inc
Bill.com Holdings Inc is a provider of cloud-based software that simplifies, digitizes, and automates financial operations for SMBs. Its artificial-intelligence enabled financial software platform used mostly to build connections between customers, suppliers, and clients. The company's platform generates and process invoices, streamline approvals, send and receive payments, sync with their accounting system, and manage their cash. The firm generates revenue through subscription and transaction fees.
Read more on BILL →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
